Human hallucinogen research: Guidelines for safety

Journal of Psychopharmacology

Volumn 22, Issue 6, 2008, Pages 603-620

  Johnson, M W ^a   Richards, W A ^b   Griffiths, R R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

5 HT2A agonists; Adverse reactions; DMT; Entheogens; Hallucinogens; Human research; LSD; Mescaline; Psilocybin; Psychedelics; Safety guidelines

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BENZILIC ACID; HARMINE; LYSERGIDE; MESCALINE; PSILOCYBINE; PSYCHEDELIC AGENT;

CLINICAL PROTOCOL; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; FAMILY HISTORY; MENTAL DISEASE; PATIENT SAFETY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK ASSESSMENT; SUPPORT GROUP; VIOLENCE;

CLINICAL TRIALS AS TOPIC; ENVIRONMENT; HALLUCINOGENS; HUMAN EXPERIMENTATION; HUMANS; PERCEPTION; PRACTICE GUIDELINES AS TOPIC; PSYCHOTIC DISORDERS; RESEARCH; SAFETY; SUBSTANCE-RELATED DISORDERS;

EID: 50249130824     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108093587     Document Type: Review

References (168)

1. Abraham, HD, Aldridge, AM (1993) Adverse consequences of lysergic acid diethylamide. Addiction 88: 1327-1334.
2. Abramson, HA (ed) (1960) The Use of LSD in Psychotherapy. New York: Josiah Macy Jr. Foundation Publications.
3. Abramson, HA (ed) (1963) The Use of LSD in Psychotherapy and Alcoholism. New York: Bobbs-Merrill.
4. Abuzzahab, FS, Anderson, BJ (1971) A review of LSD treatment in alcoholism. Int Pharmacopsychiatry 6: 223-235.
5. American Psychiatric Association (2000) DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Text Revision. Fourth ed. Washington, DC: American Psychiatric Association.
6. Baggott, MJ, Erowid, E., Erowid, F., Robertson, LC (2006) Chronic visual changes in hallucinogen users: a web-based questionnaire. Poster presented at the 2006 meeting of the College on Problems of Drug Dependence, Scottsdale, AZ.
7. Barbosa, PC, Giglio, JS, Dalgalarrondo, P. (2005) Altered states of consciousness and short-term psychological after-effects induced by the first time ritual use of ayahuasca in an urban context in Brazil. J Psychoactive Drugs 37: 193-201.
8. Bender, L., Siva Sankar, DV (1968) Chromosome damage not found in leukocytes of children treated with LSD-25. Science 159: 749.
9. Blewett, DB, Chwelos, N. (1959) Handbook for the Therapeutic Use of Lysergic Acid Diethylamide-25: Individual and Group Procedures. http://www.erowid.org/psychoactives/guides/handbook_lsd25.shtml [accessed 9.10.07].
10. Bonson, KR, Buckholtz, JW, Murphy, DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14: 425-436.
11. Bonson, KR, Murphy, DL (1996) Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 73: 229-233.
12. Buchanan, RW, Carpenter, WT (2005) Concept of Schizophrenia. In: Sadock, RJ, Sadock, VA (eds). Kaplan and Sadock's Comprehensive Textbook of Psychiatry, vol. 1, eighth ed. Philadelphia: Lippincott, William, Wilkins, pp. 1329-1345.
13. Callaway, JC, Grob, CS (1998) Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs 30: 367-369.
14. Carter, OL, Burr, DC, Pettigrew, JD, Wallis, GM, Hasler, F., Vollenweider, FX (2005 a) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 17: 1497-1508.
15. Carter, OL, Pettigrew, JD, Burr, DC, Alais, D., Hasler, F., Vollenweider, FX (2004) Psilocybin impairs high-level but not low-level motion perception. Neuroreport 15: 1947-1951.
16. Charney, DS, Mihic, SJ, Harris, RA (2006) Hypnotics and sedatives. In: Brunton, LL, Lazo, JS, Parker, KL (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, eleventh edition. New York: McGraw-Hill, pp. 401-427.
17. Chwelos, N., Blewett, DB, Smith, CM, Hoffer, A. (1959) Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quart, J Stud Alcohol 20: 577-590.
18. Cohen, MM, Hirschhorn, K., Frosch, WA (1967 a) In vivo in vitro chromosomal damage induced by LSD-25. N Engl J Med 277: 1043-1049.
19. Cohen, MM, Marinello, MJ, Back, N. (1967 b) Chromosomal damage in human leukocytes induced by lysergic acid diethylamide. Science 155: 1417-1419.
20. Cohen, S. (1960) Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis 130: 30-40.
21. Cohen, S. (1965) LSD and the anguish of dying. Harpers Mag 231: 69-78.
22. Cohen, S., Ditman, KS (1962) Complications associated with lysergic acid diethylamid (LSD-25). JAMA 181: 161-162.
23. Council on Spiritual Practices (2001) Code of ethics for spiritual guides (appendix B). In: Roberts, TB (ed). Psychoactive Sacramentals: Essays on Entheogens and Religion. San Francisco: Council on Spiritual Practices, pp. 250-251.
24. Crochet, R, Sandison, R, Walk, A (eds) (1963) Hallucinogenic Drugs and Their Psychotherapeutic Use. Springfield, IL: Thomas.
25. Dishotsky, NI, Loughman, WD, Mogar, RE, Lipscomb, WR (1971) LSD and genetic damage. Is LSD chromosome damaging, carcinogenic, mutagenic, or teratogenic. Science 172: 431-440.
26. Dittrich, A. (1993) Psychological aspects of altered states of consciousness of the LSD type: measurement of their basic dimensions and prediction of individual differences. In: Pletscher, A, Ladewig, D (eds). Fifty years of LSD Concurrent status and perspectives of hallucinogens. New York: Parthenon, pp. 101-118.
27. Dobkin de Rios, M., Grob, CS, Baker, JR (2002) Hallucinogens and redemption. J Psychoactive Drugs 34: 239-248.
28. Doblin, R. (1991) Pahnke's "Good Friday Experiment": a long-term follow-up and methodological critique. J Transpers Psychol 23: 1-28.
29. Fabing, HD (1955) New blocking agent against the development of LSD-25 psychosis. Science 121: 208-210.
30. Fantegrossi, WE, Woods, JH, Winger, G. (2004) Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol 15: 149-157.
31. Fiorella, D., Helsley, S., Rabin, RA, Winter, JC (1996) Potentiation of LSD-induced stimulus control by fluoxetine in the rat. Life Sci 59: PL283 - PL287.
32. First, MB, Spitzer, RL, Gibbon, M., Williams, JBW (2001) Structured clinical interview for DSM-IV-TR Axis 1 Disorders Research Version Patient Edition (SCID-I/P) Biometrics Research. New York: New York State Psychiatric Institute.
33. Fischman, MW, Johanson, CE (1998) Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers. Behav Pharmacol 9: 479-498.
34. Frecska, E., Luna, LE (2006) The adverse effects of hallucinogens from intramural perspective. Neuropsychopharmacol Hung 8: 189-200.
35. Funderburk, FR, Griffiths, RR, McLeod, DR, Bigelow, GE, Mackenzie, A., Liebson, IA, et al. (1988) Relative abuse liability of lorazepam and diazepam: an evaluation in 'recreational' drug users. Drug Alcohol Depend 22: 215-222.
36. Gable, RS (1993) Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. Am JDrug Alcohol Abuse 19: 263-281.
37. Gable, RS (2004) Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 99: 686-696.
38. Glennon, RA, Titeler, M., McKenney, JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505-2511.
39. Gonzales, VO Centro Espirita Beneficiente União do Vegetal 546 US (2006). US Supreme Court, no 04-1084, decided 21 February 2006.
40. González-Maeso, J., Weisstaub, NV, Zhou, M., Chan, P., Ivic, L., Ang, R., et al. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53: 439-452.
41. Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Daumann, J., et al. (2006) Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis. Neuropsychopharmacology 31: 431-441.
42. Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., et al. (2005) Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT). a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38: 301-311.
43. Gouzoulis-Mayfrank, E., Heekeren, K., Thelen, B., Lindenblatt, H., Kovar, KA, Sass, H., et al. (1998 a) Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol 9: 561-566.
44. Gouzoulis-Mayfrank, E., Schneider, F., Friedrich, J., Spitzer, M., Thelen, B., Sass, H. (1998 b) Methodological issues of human experimental research with hallucinogens. Pharmacopsychiatry 31: 114-118.
45. Gouzoulis-Mayfrank, E., Thelen, B., Habermeyer, E., Kunert, HJ, Kovar, KA, Lindenblatt, H., et al. (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethyl amphetamine (MDE). psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142: 41-50.
46. Gouzoulis-Mayfrank, E., Thelen, B., Maier, S., Heekeren, K., Kovar, KA, Sass, H., et al. (2002) Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology 45: 205-212.
47. Greenblatt, DJ, Shader, RI (1985) Clinical pharmacokinetics of the benzodiazepines. In: Smith, DE, Wesson, DR (eds). The Benzodiazepines: Current Standards for Medical Practice. Lancaster, PA: MTP Press, pp. 43-58.
48. Griffiths, RR, Bigelow, GE, Henningfield, JE (1980) Similarities in animal and human drug-taking behavior. Adv Subst Abuse 1: 1-90.
49. Griffiths, RR, Richards, WA, McCann, U., Jesse, R. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187: 268-283.
50. Grinspoon, L., Bakalar, JB (1979) Psychedelic Drugs Reconsidered. New York: Basic Books.
51. Grob, CS (2005) Psilocybin research with advanced-stage cancer patients. Multidisciplinary Association for Psychedelic Studies (MAPS) Bulletin 15 (3). 8.
52. Grob, CS, Greer, GR, Mangini, M. (1998) Hallucinogens at the turn of the century: an introduction. J Psychoactive Drugs 30: 315-319.
53. Grob, CS, McKenna, DJ, Callaway, JC, Brito, GS, Neves, ES, Oberlaender, G., et al. (1996) Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 184: 86-94.
54. Grof, S. (1977) Perinatal roots of wars, totalitarianism, and revolutions: observations from LSD research. J Psychohist 4: 269-308.
55. Grof, S. (1980) LSD Psychotherapy. Pomona, CA: Hunter House.
56. Grof, S., Goodman, LE, Richards, WA, Kurland, AA (1973) LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 8: 129-144.
57. Grof, S., Halifax, J. (1977) The Human Encounter with Death. New York: EP Dutton.
58. Gutstein, HB, Akil, H. (2006) Opioid analgesics. In: Brunton, LL, Lazo, JS, Parker, KL (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, eleventh ed. New York: McGraw-Hill, pp. 547-590.
59. Halpern, JH (1996) The use of hallucinogens in the treatment of addiction. Addict Res 4: 177-189.
60. Halpern, JH, Pope, HG (1999) Do hallucinogens cause residual neuro-psychological toxicity. Drug Alcohol Depend 53: 247-256.
61. Halpern, JH, Pope, HG (2003) Hallucinogen persisting perception disorder: what do we know after 50 years. Drug Alcohol Depend 69: 109-119.
62. Halpern, JH, Sherwood, AR, Hudson, JI, Yurgelun-Todd, D., Pope, HG (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry 58: 624-631.
63. Harner, MJ (1962) Jivaro Souls. Am Anthropol 64: 258-272.
64. Harner, MJ (1968) The sound of rushing water. Natural History Magazine, 77: 28-33, 60-61.
65. Harvard Mental Health Letter (2006) Reviving the study of hallucinogens (editorial). Harv Ment Health Lett 23: 5.
66. Hasler, F., Bourquin, D., Brenneisen, R., Bär, T., Vollenweider, FX (1997) Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv 72: 175-184.
67. Hasler, F., Bourquin, D., Brenneisen, R., Vollenweider, FX (2002) Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. J Pharm Biomed Anal 30: 331-339.
68. Hasler, F., Grimberg, U., Benz, MA, Huber, T., Vollenweider, FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172: 145-156.
69. Hidalgo, WT (1960) Estudio comparativo psicofisiologico de la mescalina, dietilamida del acido D-lisérgico y psilocybina. Acta Med Venez 8: 56-62.
70. Hoch, PH, Pennes, HH, Cattell, JP (1953) Psychoses produced by administration of drugs. Res Publ Assoc Res Nerv Ment Dis 32: 287-296.
71. Hoffer, A., Callbeck, MJ (1960) Drug-induced schizophrenia. J Ment Sci 106: 138-159.
72. Hollister, LE (1961) Clinical, biochemical and psychologic effects of psilocybin. Arch Int Pharmacodyn Ther 130: 42-52.
73. Hollister, LE, Hartman, AM (1962) Mescaline, lysergic acid diethylamide and psilocybin: comparison of clinical syndromes, effects on color perception and biochemical measures. Compr Psychiatry 3: 235-241.
74. Hollister, LE, Shelton, J., Krieger, G. (1969) A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics. Am J Psychiatry 125: 1352-1357.
75. Irwin, S., Egozcue, J. (1967) Chromosomal abnormalities in leukocytes from LSD-25 user. Science 157: 313-314.
76. Isbell, H. (1959) Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia 1: 29-38.
77. Kast, E. (1967) Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide. Psychiatr Q 41: 646-657.
78. Kast, EC, Collins, VJ (1964) Lysergic acid diethylamide as an analgesic agent. Anesth Analg 43: 285-291.
79. Keeler, MH, Reifler, CB (1967) Suicide during an LSD reaction. Am J Psychiatry 123: 884-885.
80. Kuramochi, H., Takahashi, R. (1964) Psychopathology of LSD intoxication; Study of experimental psychosis induced by LSD-25: description of LSD symptoms in normal oriental subjects. Arch Gen Psychiatry 11: 151-161.
81. Kurland, AA (1985) LSD in the supportive care of the terminally ill cancer patient. J Psychoactive Drugs 17: 279-290.
82. Kurland, A., Savage, C., Pahnke, WN, Grof, S., Olsson, JE (1971) LSD in the treatment of alcoholics. Pharmakopsychiatr Neuropsychopharmakol 4: 83-94.
83. Kurland, AA, Grof, S., Pahnke, WN, Goodman, LE (1973) Psychedelic drug assisted psychotherapy. In: Goldberg, IK, Malitz, S, Kutscher, AH (eds). Patients With Terminal Cancer Psychotheramacological Agents for the Terminally Ill and Bereaved. New York: Columbia University Press, pp. 86-133.
84. Kurland, AA, Pahnke, WN, Unger, S., Savage, C., Goodman, E. (1969) Psychedelic psychotherapy (LSD) in the treatment of the patient with a malignancy. In: Cerletti, A, Bove, FJ (eds). The Present Status of Psychotropic Drugs: Pharmacological and Clinical Aspects. Amsterdam, Holland: Excerpta Medica, pp. 432-434.
85. Lancet (2006) Reviving research into psychedelic drugs (editorial). Lancet 367: 1214.
86. Leary, T. (1964) The religious experience: Its production and interpretation. Psychedelic Rev 1: 324-346.
87. Leary, T., Litwin, GH, Metzner, R. (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137: 561-573.
88. Leary, T., Metzner, R., Alpert, R. (1964) The Psychedelic Experience: A Manual Based on the Tibetan Book of the Dead. New York: Citadel Press.
89. Lee, MA, Shlain, B. (1992) Acid dreams: The Complete Social History of LSD: The CIA, the Sixties, and Beyond, Revised Edition. New York: Grove Press.
90. Lerner, AG, Gelkopf, M., Skladman, I., Oyffe, I., Finkel, B., Sigal, M., et al. (2002) Flashback and hallucinogen persisting perception disorder: clinical aspects and pharmacological treatment approach. Isr JPsychiatry Relat Sci 39: 92-99.
91. Leuner, H. (1962) Die Experimentelle Psychose. Berlin: Springer.
92. Long, SY (1972) Does LSD induce chromosomal damage and malformations? a review of the literature. Teratology 6: 75-90.
93. Lowy, B. (1971) New records of mushroom stones from Guatemala. Mycologia 63: 983-993.
94. Ludwig, A., Levine, J., Stark, L., Lazar, R. (1969) A clinical study of LSD treatment in alcoholism. Am J Psychiatry 126: 59-69.
95. Malitz, S., Esecover, H., Wilkens, B., Hoch, H. (1960) Some observations on psilocybin: a new hallucinogen in volunteer subjects. Compr Psychiatry 1: 8-17.
96. Mangini, M. (1998) Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs 30: 381-418.
97. Masters, REL, Houston, J. (1966) The Varieties of Psychedelic Experience. New York: Holt, Rinehart & Winston.
98. McCabe, OL (1977) Psychedelic drug crises: toxicity and therapeutics. J Psychedelic Drugs 9: 107-121.
99. McGlothlin, WH, Arnold, DO (1971) LSD revisited A ten-year follow-up of medical LSD use. Arch Gen Psychiatry 24: 35-49.
100. Metzner, R. (1985) Forward. In: Adamson, S (ed). Through the Gateway of the Heart: Accounts of Experiences with MDMA and other Empathogenic Substances. San Francisco: Four Trees Press.
101. Metzner, R. (2004) Introduction: visionary mushrooms of the Americas. In: Metzner, R, Darling, DC (eds). Teonanácatl: Sacred Mushroom of Visions. El Verano, CA: Four Trees Press, pp. 1-48.
102. Metzner, R., Litwin, G., Weil, G. (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5: 3-39.
103. Middlefell, R. (1967) The effects of LSD on body sway suggestibility in a group of hospital patients. Br J Psychiatry 113: 277-280.
104. Mogar, RE, Aldrich, RW (1969) The use of psychedelic agents with autistic schizophrenic children. Psychedelic Rev 10: 5-13.
105. Moreno, FA, Wiegand, CB, Taitano, EK, Delgado, PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67: 1735-1740.
106. Morris, K. (2006) Hallucinogen research inspires "neurotheology ". Lancet Neurol 5: 732.
107. Moss, EL, Dobson, KS (2006) Psychology, spirituality, and end-of-life care: an ethical integration? Can Psychol 47: 284-299.
108. National Institute on Drug Abuse (2001) Hallucinogens and dissociative drugs. National Institute on Drug Abuse, Research Report Series NIH Publication No 01-4209.
109. National Institute on Drug Abuse (2006) LSD, NIDA Infofacts. Rockville, MD: National Institute on Drug Abuse.
110. Nichols, DE (2004) Hallucinogens. Pharmacol Ther 101: 131-181.
111. Nichols, DE, Hoffman, AJ, Oberlender, RA, Jacob, P., Shulgin, AT (1986) Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem 29: 2009-2015.
112. Novak, SJ (1997) LSD before Leary: Sidney Cohen's critique of 1950s psychedelic drug research. Isis 88: 87-110.
113. Ott, J. (1996) Pharmacotheon: Entheogenic Drugs, their Plant Sources and History. Kennewick, WA: Natural Products Co.
114. O'Brien, CP (2006) Drug addiction and drug abuse. In: Brunton, LL, Lazo, JS, Parker, KL (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, eleventh ed. New York: McGraw-Hill, pp. 607-627.
115. Pahnke, W. (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the PhD in Religion and Society.
116. Pahnke, WN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin 5: 149-162.
117. Pahnke, WN, Kurland, AA, Goodman, LE, Richards, WA (1969) LSD-assisted psychotherapy with terminal cancer patients. In: Hicks, RE, Fink, PJ (eds). Psychedelic Drugs: Proceedings of a Hahnemann Medical College and Hospital Symposium. New York: Grune & Stratton, pp. 33-42.
118. Passie, T., Seifert, J., Schneider, U., Emrich, HM (2000) The pharmacology of psilocybin. Addict Biol 7: 357-364.
119. Patel, JK, Pinals, DA, Breier, A. (2003) Schizophrenia and other psychoses. In: Tasman, A, Kay, J, Lieberman, JA (eds). Psychiatry, Vol. 2. Second ed. New Jersey: John Wiley & Sons, Ltd, pp. 1131-1206.
120. Poling, A., Bryceland, J. (1979) Voluntary drug self-administration by nonhumans: a review. J Psychedelic Drugs 11: 185-190.
121. Reitman, J., Vasilakis, A. (2004) The lost freshman. Rolling Stone Magazine, 944: 62-66.
122. Reynolds, PC, Jindrich, EJ (1985) A mescaline associated fatality. J Anal Toxicol 9: 183-184.
123. Rhead, JC (1977) The use of psychedelic drugs in the treatment of severely disturbed children: a review. J Psychedelic Drugs 9: 93-101.
124. Riba, J., Rodriguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., et al. (2001) Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology 154: 85-95.
125. Richards, WA (1980) Psychedelic Drug-assisted psychotherapy with persons suffering from terminal cancer. J Altered States Conscious 5: 309-319.
126. Richards, WA (2003) Entheogens in the study of mystical and archetypal experiences: Research in the Social Scientific Study of Religion. Brill 13: 143-155.
127. Richards, WA (2005) Entheogens in the study of religious experiences: current status. J Religion Health 44: 377-389.
128. Richards, WA, Grof, S., Goodman, LE, Kurland, AA (1972) LSD-Assisted psychotherapy and the human encounter with death. J Transpers Psychol 4: 121-150.
129. Richards, WA, Rhead, JC, DiLeo, FB, Yensen, R., Kurland, AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9: 1-10.
130. Richards, WA, Rhead, JC, Grof, S., Goodman, LE, Di Leo, F., Rush, L. (1979) DPT as an adjunct in brief psychotherapy with cancer patients. Omega 10: 9-26.
131. Rinkel, M., Atwell, CR, DiMascio, A., Brown, J. (1960) Experimental Psychiatry, VPsilocybine: A New Psychotogenic Drug. N Engl J Med 262: 295-299.
132. Roberts, TB, Jesse, RN (1997) Recollections of the Good Friday Experiment: an interview with Huston Smith. J Transpers Psychol 29: 99-104.
133. Ruck, CA, Bigwood, J., Staples, D., Ott, J., Wasson, RG (1979) Entheogens. J Psychedelic Drugs 11: 145-146.
134. Rümmele, W., Gnirss, F. (1961) Untersuchungen mit Psilocybin, ein psychotropen Substanz aus Psilocybe Mexicana. Schweiz Arch Neurol Neurochir Psychiatr 87: 365-385.
135. Savage, C., McCabe, OL (1973) Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study. Arch Gen Psychiatry 28: 808-814.
136. Schultes, RE (1969) Hallucinogens of plant origin. Science 163: 245-254.
137. Schultes, RE, Hoffman, A., Rätsch, C. (2001) Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers, Revised Edition. Rochester, VT: Healing Arts Press.
138. Sessa, B. (2005) Can psychedelics have a role in psychiatry once again. Br J Psychiatry 186: 457-458.
139. Shulgin, AT, Shulgin, A. (1991) Pihkal: A Chemical Love Story. Berkeley, CA: Transform Press.
140. Shulgin, AT, Shulgin, A. (1997) Tihkal: The Continuation. Berkeley, CA: Transform Press.
141. Sjoberg, BM, Hollister, LE (1965) The effects of psychotomimetic drugs on primary suggestibility. Psychopharmacologia 8: 251-262.
142. Smart, RG, Storm, T., Baker, EFW, Solursh, L. (1966) A controlled study of lysergid in the treatment of alcoholism: The effects on drinking behavior. Quart J Stud Alcohol 27: 469-485.
143. Smith, H. (2000) Cleansing the Doors of Perceptions: The Religious Significance of Entheogenic Plants and Chemicals. New York: Penguin Putnam Inc.
144. Snyder, SH (1988) Psychotogenic drugs as models for schizophrenia. Neuropsychopharmcology 1: 197-199.
145. Stockings, GT (1940) A clinical study of the mescaline psychosis, with special reference to the mechanism of the genesis of schizophrenia and other psychotic states. J Mental Sciences 86: 29-47.
146. Stolaroff, MJ (2004) The Secret Chief Revealed: Conversations with Leo Zeff, Pioneer in the Underground Psychedelic Therapy Movement. Multidisciplinary Association for Psychedelic Studies (MAPS), Sarasota, FL.
147. Stolz, J., Marsden, C., Middlemiss, D. (1983) Effect of chronic antidepressant treatment and subsequent withdrawal on [3H]5-hydroxytryptamine and [3H]-spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour. Psychopharmacology 80: 150-155.
148. Strassman, RJ (1984) Adverse reactions to psychedelic drugs: a review of the literature. J Nerv Ment Dis 172: 577-595.
149. Strassman, RJ (1991) Human hallucinogenic drug research in the United States: a present-day case history and review of the process. J Psychoactive Drugs 23: 29-38.
150. Strassman, RJ (1992) Human hallucinogen interactions with drugs affecting serotonergic neurotransmission. Neuropsychopharmacology 7: 241-243.
151. Strassman, RJ (1996) Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 73: 121-124.
152. Strassman, RJ (2001) DMT: The Spirit Molecule. Rochester, VT: Park Street Press.
153. Strassman, RJ, Qualls, CR (1994) Dose-response study of N,N-dimethyltryptamine in humans: neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry 51: 85-97.
154. Strassman, RJ, Qualls, CR, Berg, LM (1996) Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry 39: 784-795.
155. Strassman, RJ, Qualls, CR, Uhlenhuth, EH, Kellner, R. (1994) Dose-response study of N,N-dimethyltryptamine in humans II: subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51: 98-108.
156. Umbricht, D., Vollenweider, FX, Schmid, L., Grubel, C., Skrabo, A., Huber, T., et al. (2003) Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 28: 170-181.
157. Ungerleider, JT, Frank, IM (1976) Management of acute panic reactions and drug flashbacks resulting from LSD ingestion. In: Bourne, P (ed). Acute Drug Emergencies. New York: Academic Press, pp. 133-138.
158. Tjio, JH, Pahnke, WN, Kurland, AA (1969) LSD and chromosomes, A controlled experiment. JAMA 210: 849-856.
159. Vollenweider, FX, Csomor, PA, Knappe, B., Geyer, MA, Quednow, BB (2007) The effects of preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 32: 1876-1887.
160. Vollenweider, FX, Geyer, MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56: 495-507.
161. Vollenweider, FX, Leenders, KL, Scharfetter, C., Maguire, P., Stadelmann, O., Angst, J. (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357-372.
162. Vollenweider, FX, Vollenweider-Scherpenhuyzen, MFI, Bäbler, A., Vogel, H., Hell, D. (1998) Psilocybin induces schizophrenia-like psychosis in humans via serotonin-2 agonist action. Neuroreport 8: 3897-3902.
163. Vollenweider, FX, Vontobel, P., Hell, D., Leenders, KL (1999) 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man - a PET study with [11C]raclopride. Neuropsychopharmacology 20: 424-433.
164. Weil, A. (2004) The Natural Mind: A Revolutionary Approach to the Drug Problem, Revised Edition. Boston, MA: Houghton Mifflin Co.
165. Winkelman, MJ, Roberts, TB (eds) (2007) Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments. Westport, CT: Praeger.
166. Wittmann, M., Carter, O., Hasler, F., Cahn, BR, Grimberg, U., Spring, P., et al. (2007) Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol 21: 50-64.
167. Wolbach, AB, Isbell, H., Miner, EJ (1962 a) Cross tolerance between mescaline and LSD-25 with a comparison of the mescaline and LSD reactions. Psychopharmacologia 3: 1-14.
168. Wolbach, AB, Miner, EJ, Isbell, H. (1962 b) Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia 3: 219-223.